文献速递血栓与止血

癌症相关静脉血栓形成后的生存:斯堪的纳维亚血栓与癌症研究

Survival after cancer-related venous thrombosis: the Scandinavian Thrombosis and Cancer Study.
PubMed 文献 · Blood Adv · 2023-01-01

基于斯堪的纳维亚血栓与癌症(STAC)人群队列144 952名既往无VTE或癌症的参与者,随访平均11.7年,期间14 621人发生癌症、2444人发生VTE(其中1241例为癌症相关VTE)。癌症相关VTE患者死亡风险较仅癌症患者增加3.4倍,且在各类癌症中VTE均升高死亡风险2.8至14.7倍。

要点

  • 癌症相关VTE患者死亡率为45.3/100人年,仅癌症患者为9.2/100人年。
  • 与仅癌症患者相比,癌症相关VTE患者死亡风险增加3.4倍。
  • 各类癌症中VTE均增加死亡风险,幅度为2.8至14.7倍。

核心结论

  • 在一般人群中,合并VTE的癌症患者死亡风险较不合并VTE的癌症患者高3.4倍,且独立于癌症类型。

研究设计与样本

  • 斯堪的纳维亚血栓与癌症(STAC)队列为人群基础队列,纳入144 952名既往无VTE或癌症的参与者,随访期间登记癌症与VTE发生情况。
  • 采用以癌症和VTE为时变暴露的Cox回归模型计算死亡风险比,并按癌症类型、分期及VTE类型(深静脉血栓或肺栓塞)进行亚组分析。

主要发现

  • 随访平均11.7年期间,14 621名参与者发生癌症,2444名发生VTE,其中1241例为癌症相关VTE。
  • 无病参与者、仅VTE、仅癌症、癌症相关VTE的死亡率分别为0.63、5.0、9.2、45.3/100人年。
  • 与仅癌症患者相比,癌症相关VTE患者死亡风险增加3.4倍。
  • 在所有癌症类型中,VTE的发生使死亡风险增加2.8至14.7倍。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with cancer have an increased risk of developing venous thromboembolism (VTE), and this combination is reported to result in poorer survival compared with cancer alone. This study aimed to investigate the impact of VTE on the survival of patients with cancer in a general population. The Scandinavian Thrombosis and Cancer (STAC) cohort, a population-based cohort including 144 952 participants without previous VTE or cancer, was used. During follow-up, cancer and VTE incidences were registered. "Cancer-related VTE" was defined as VTE diagnosed in patients with overt or occult cancer. The survival of participants without cancer and/or VTE ("disease-free") was compared with the survival of participants with cancer and cancer-related VTE. Cox regression models with cancer and VTE as time-varying exposures were performed to calculate hazard ratios for death. Subanalyses were performed across cancer types and stages and VTE type (deep vein thrombosis or pulmonary embolism). During follow-up (mean, 11.7 years), 14 621 participants developed cancer, and 2444 developed VTE, of which 1241 were cancer-related. The mortality rates (per 100 person years) for disease-free participants, VTE only, cancer only, and cancer-related VTE were 0.63, 5.0, 9.2, and 45.3, respectively. Compared with patients with cancer only, the risk of death for patients with cancer-related VTE was increased 3.4-fold. Within all cancer types, the occurrence of VTE increased the mortality risk 2.8- to 14.7-fold. In a general population, patients with cancer with VTE had a 3.4-fold higher mortality risk than patients with cancer without VTE, independent of cancer type.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Crobach MJT, Anijs RJS, Brækkan SK, et al. Survival after cancer-related venous thrombosis: the Scandinavian Thrombosis and Cancer Study. Blood Adv. 2023. PMID: 37013958. doi:10.1182/bloodadvances.2022009577

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。